| Market Cap | 12.29M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -4.14M | Forward P/E | - | EPS next Y | 27.30% | 50D Avg Chg | 5.00% |
| Sales | 507.2k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -6.00% |
| Dividend | N/A | Price/Book | 3.22 | EPS next 5Y | - | 52W High Chg | -72.00% |
| Recommedations | 2.00 | Quick Ratio | 2.54 | Shares Outstanding | 8.10M | 52W Low Chg | 27.00% |
| Insider Own | 35.49% | ROA | -93.77% | Shares Float | 4.67M | Beta | - |
| Inst Own | 7.87% | ROE | -171.56% | Shares Shorted/Prior | 120.54K/48.77K | Price | 2.14 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 9,643 | Target Price | 2.00 |
| Oper. Margin | -697.93% | Earnings Date | - | Volume | 6,432 | Change | 1.90% |
Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.
| Maxim Group | Buy | Apr 9, 24 |